Abstract 1254: Preclinical studies with TGN-1062, a selective and reversible small molecule inhibitor of CDK7
Ryan L. Rodriguez del Villar(Translational Genomics Research Institute), Sunil Sharma(Translational Genomics Research Institute), Alexis Weston(Translational Genomics Research Institute), Mohan R. Kaadige(Translational Genomics Research Institute), Vincent Chung(City of Hope), Trason Thode(Translational Genomics Research Institute), Serina Ng(Translational Genomics Research Institute), Raffaella Soldi(Banner Health), Srinivas Rao Kasibhatla(Translational Genomics Research Institute), Daniel D. Von Hoff(Translational Genomics Research Institute), Joseph Chao(Amgen (United States))
Cited by 1
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
|Annals of Oncology|1996|569